• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Carter Ledyard & Milburn LLP

  • Professionals
  • Practices
  • News & Insights
  • Thought Leadership
  • Featured Series
  • Looking Ahead
  • Events
  • Our Firm
Stay Connected
Stay Connected
Subscribe To Our Publications
PrintPDFEmail

Carter Ledyard Represents Trinity Biotech in its $45 Million Strategic Investment and Partnership with MiCo Group

May 4, 2022/less than a minute

Carter Ledyard represented long-time client, Trinity Biotech plc (Nasdaq: TRIB), a leading global diagnostic company, in the Company’s $45 million strategic investment and partnership with MiCo Ltd (“MiCo”) that closed on May 3, 2022. MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed. In addition to approximately $25 million of newly issued equity, the Company issued a seven-year, unsecured junior convertible note in the amount of $20 million, with a fixed interest rate of 1.5% and an ADS conversion price of $3.24 per ADS.  Following the investment, MiCo will hold 29.9% of the voting share capital of the Company. 

Co-Chair of Carter Ledyard’s Corporate Practice Group, Steven Glusband, led the deal and was supported by counsel Mary Brown. 

  • LinkedIn
  • Twitter
  • Facebook

sidebar

Related Practices

  • Corporate
  • Mergers and Acquisitions

Related Professionals

  • Media item displaying Steven J. Glusband

    Steven J. Glusband

    /

    Partner

    D/212-238-8605
    glusband@clm.com
  • Media item displaying Mary W. Brown

    Mary W. Brown

    /

    Counsel

    D/212-238-8765
    mbrown@clm.com
Copyright © 2023 Carter Ledyard & Milburn LLPPowered by Content Pilot
  • Sitemap
  • Disclaimer
  • Cookie Policy
  • Privacy Policy
  • Subscribe
  • Contact

Meritas

Meritas.org Logo

Legal Link

Legal link dot org logo